Chen F, Puett D
Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Florida 33101.
J Biol Chem. 1991 Apr 15;266(11):6904-8.
The choriogonadotropin beta subunit is unique in the human glycoprotein hormone family in containing a carboxyl-terminal extension, with four sites of O-glycosylation, that is not present in the other beta subunits. We have used site-directed mutagenesis to define boundaries on the extent to which truncations can be made at the COOH terminus without abolishing subunit assembly and biological activity. Two COOH-terminal deletion mutant chains of human choriogonadotropin beta, des(93-145) and des(101-145), were prepared and expressed in Chinese hamster ovary cells containing a stably integrated gene for bovine alpha. The heterologous gonadotropin, bovine alpha-human choriogonadotropin des(101-145) beta, formed a heterodimer and, when assayed with transformed murine Leydig cells in vitro, competed with the binding of standard human choriogonadotropin and stimulated both cAMP and progesterone production, albeit with a reduced potency relative to bovine alpha-human choriogonadotropin beta wild type. In contrast, human choriogonadotropin des(93-145) beta, expressed under identical conditions in the presence of bovine alpha, failed to form heterodimer and thus exhibited no competitive binding and was without effect on cAMP and progesterone levels. Consequently, removal of the putative determinant loop region of the beta subunit (residues 93-100), which is believed to be important in determining receptor specificity, abolishes association with alpha. Hence, in addition to its possible role as a receptor determinant, this region of the molecule appears to be critical for proper folding or subunit interaction. The truncated form of human choriogonadotropin beta lacking residues 101-145 is the shortest form of the subunit yet described that retains biological activity. Moreover, these results demonstrate that the proposed disulfide between Cys-26 and Cys-110 is not required for subunit assembly or for receptor binding and subsequent intracellular signaling.
绒毛膜促性腺激素β亚基在人糖蛋白激素家族中是独特的,它含有一个羧基末端延伸区,有四个O-糖基化位点,而其他β亚基中不存在该延伸区。我们利用定点诱变来确定在不消除亚基组装和生物活性的情况下,COOH末端可进行截短的范围边界。制备了两条人绒毛膜促性腺激素β的COOH末端缺失突变链,即des(93 - 145)和des(101 - 145),并在中国仓鼠卵巢细胞中表达,该细胞含有一个稳定整合的牛α基因。异源促性腺激素,即牛α-人绒毛膜促性腺激素des(101 - 145)β,形成了异二聚体,并且当在体外与转化的小鼠睾丸间质细胞一起检测时,它与标准人绒毛膜促性腺激素的结合竞争,并刺激了cAMP和孕酮的产生,尽管相对于牛α-人绒毛膜促性腺激素β野生型其效力有所降低。相比之下,在相同条件下,在有牛α存在时表达的人绒毛膜促性腺激素des(93 - 145)β未能形成异二聚体,因此没有表现出竞争结合,并且对cAMP和孕酮水平没有影响。因此,去除β亚基的假定决定簇环区域(第93 - 100位氨基酸残基),据信该区域对于确定受体特异性很重要,会消除与α亚基的结合。因此,除了其作为受体决定簇的可能作用外,该分子区域似乎对于正确折叠或亚基相互作用也至关重要。缺少第101 - 145位氨基酸残基的人绒毛膜促性腺激素β截短形式是迄今描述的保留生物活性的最短亚基形式。此外,这些结果表明,Cys - 26和Cys - 110之间提议的二硫键对于亚基组装或受体结合以及随后的细胞内信号传导不是必需的。